ProJenX
Healthcare & Life Sciences
Recent Finacing
Series A
Recent Raise
$15M
ProJenX is a biotechnology company developing a lead compound, prosetin, for the treatment of ALS and other brain diseases, with funding from a $15 million Series A financing round led by Medical Excellence Capital and collaboration with Project ALS and Columbia University.
Focus Areas
Clinical-stage biotechnology
ALS treatment development
Brain diseases treatment
Pharmaceutical research
Collaboration with universities
Board management
Investors
